Every material Form 8-K Thermo Fisher Scientific filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On December 1, 2025, Thermo Fisher's finance subsidiary issued €1.0 billion of floating rate notes due 2027 and €1.1 billion of 3.628% fixed rate notes due 2035 in a public offering, with the parent company fully and unconditionally guaranteeing them. The company expects net proceeds of approximately €2.09 billion for general corporate purposes, which may include acquisitions, debt repayment and refinancing, working capital, capital expenditures, or share repurchases.
Floating Rate Senior Notes: €1.0 billion, maturing December 1, 2027, with quarterly interest beginning March 1, 2026
3.628% Senior Notes: €1.1 billion, maturing December 1, 2035, with annual interest beginning December 1, 2026
Expected net proceeds of approximately €2.09 billion, per the filing
Notes issued by Thermo Fisher (Finance I) B.V. under a supplemental indenture dated December 1, 2025, with The Bank of New York Mellon Trust Company as trustee
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Thermo Fisher Scientific filing is on SEC EDGAR ↗. 8-K briefs of other companies →